• Rolled out AI-driven discovery and protein-engineering tools to speed design of tumor-targeting engagers and multi-domain proteins, aiming to cut development costs.
• AI-guided sequence and structure screening prioritizes de novo candidates with stronger binding, stability, manufacturability, reducing trial-and-error work.
• Uses modeling to optimize domain orientation, linker design, spatial architecture to improve immune synapse formation while limiting structural liabilities.
• Targets multiple new development candidates entering pre-IND development in 2027, with potential expansion beyond oncology indications.
• GTB-3650 and GTB-5550 remain in Phase 1 this year, positioning next-generation programs as the next pipeline value driver.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010800PRIMZONEFULLFEED9729026) on June 01, 2026, and is solely responsible for the information contained therein.